Navigation Links
Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
Date:3/1/2011

SAN DIEGO, March 1, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 31st Annual Cowen & Company Healthcare Conference on Tuesday, March 8, 2011 at 8:45 a.m. EST (5:45 a.m. PST).  The conference is being held at the Boston Marriot Copley Place Hotel.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs.

The presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through March 22, 2011.  

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys has initiated a Phase IIb study of ANA598, the Company's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q for the quarter ended September 30, 2010.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Alzheimer Diagnostic Tests - Medical Devices ... Devices sector report , "Alzheimer Diagnostic Tests - ... of Alzheimer Diagnostic Tests currently in pipeline stage. ... pipeline products with comparative analysis of the products ... major players involved in the pipeline product development. ...
(Date:2/8/2016)... , Feb. 8, 2016 CBG Technologies, ... PW Series Solvent Recycling Systems, specifically designed for ... integration with new and existing vapor degreasers, parts ... consistently-fresh solvent through continuous recycling and recovers 100% ... --> --> Precision parts manufacturers ...
(Date:2/8/2016)... India , February 8, 2016 ... a new market research report "Ablation Technologies Market by ... (Csardiovascular, Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - ... studies the global market over the forecast period of ... $4.44 Billion by 2020, at CAGR of 10.5% from ...
Breaking Medicine Technology:
(Date:2/9/2016)... Cambridge, MA (PRWEB) , ... February 09, 2016 ... ... Institute (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for ... medical services covered in the report, Evaluation of the 2015 Fee Schedule ...
(Date:2/9/2016)... Fairfax, VA (PRWEB) , ... February 09, 2016 , ... ... Maryland. The family scheduled an appointment after they noticed their furnace not producing any ... a cracked heat exchanger. The cracked heat exchanger was leaking dangerous levels of carbon ...
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has published ... have a basic understanding of the techniques they use so they can more ... them reduce waste and rework to create a leaner overall lab experience. ...
(Date:2/9/2016)... Rosa, California (PRWEB) , ... February 09, 2016 , ... ... rated one of the highest preliminary data vendors in the latest KLAS report, Population ... years, i2i has led the developing market for population health management (PHM). The ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Human Nutrition into the Food & Beverage and Dietary Supplement ... channel partner throughout Canada and USA geographies east of the Rocky Mountains since ...
Breaking Medicine News(10 mins):